Biomedical papers, 2017 (vol. 161), issue 2

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017, 161(2):144-151 | 10.5507/bp.2017.026

Effects of obesity on liver cytochromes P450 in various animal models

Veronika Tomankovaa, Pavel Anzenbacherb, Eva Anzenbacherovaa
a Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
b Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic

The prevalence of obesity and other obesity-related diseases is increasing worldwide. Obesity is a disease characterized by increased body weight, or a condition resulting from excessive accumulation of body fat. Due to increased body fat deposits, obesity has also been associated with increased mortality resulting from higher incidence rates of hypertension, diabetes, or various types of cancer, such as breast, colorectal, cervical and prostate cancer. Physiological changes associated with obesity are likely to result in altered drug biotransformation. The main enzymes enabling the oxidative biotransformation of most drugs are cytochromes P450 (CYPs). The review summarizes how pathophysiological factors, especially obesity, affect properties (e.g. enzyme activity, protein expression, gene expression) of CYP enzymes in various experimental models of human obesity. Results reported by various authors suggest that obesity is associated with a decrease of CYP activities (except for the CYP2C and CYP2E1 enzymes). The only exception is mouse obesity induced by monosodium glutamate (administered to newborn mice) as it usually leads to increased CYP expression. Selecting an animal model that is as close as possible to the properties of human obesity is of paramount importance.

Keywords: obesity, animal model, cytochrome P450, drug metabolism, enzyme activity, protein level, mRNA level

Received: June 14, 2016; Accepted: May 11, 2017; Prepublished online: May 25, 2017; Published: June 14, 2017


Attachments:

Download fileBiomed161-2-TOMANKOVA-SUPP.pdf

File size: 181.84 kB

References

  1. Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm 2010;2010. Go to original source... Go to PubMed...
  2. Morrish GA, Pai MP, Green B. The effects of obesity on drug pharmacokinetics in humans. Expert Opin Drug Metab Toxicol 2011;7(6):697-706. Go to original source... Go to PubMed...
  3. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes 2013;2013:291546. Go to original source... Go to PubMed...
  4. Tahergorabi Z, Khazaei M. The relationship between inflammatory markers, angiogenesis, and obesity. ARYA Atheroscler 2013;9(4):247-53. Go to PubMed...
  5. Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci 1999;88(1):1-7. Go to original source... Go to PubMed...
  6. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348(17):1625-38. Go to original source... Go to PubMed...
  7. Jain R, Chung SM, Jain L, Khurana M, Lau SW, Lee JE, Vaidyanathan J, Zadezensky I, Choe S, Sahajwalla CG. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther 2011;90(1):77-89. Go to original source... Go to PubMed...
  8. Finkelstein EA, Khavjou OA, Thompson H, Trogdon JG, Pan L, Sherry B, Dietz W. Obesity and severe obesity forecasts through 2030. Am J Prev Med 2012;42(6):563-70. Go to PubMed...
  9. Ghose R. Clinical consequences of altered drug disposition in obesity. J Clin Trials 2013;2:e107.
  10. Tomankova V, Liskova B, Skalova L, Bartikova H, Bousova I, Jourova L, Anzenbacher P, Ulrichova J, Anzenbacherova E. Altered cytochrome P450 activities and expression levels in the liver and intestines of the monosodium glutamate-induced mouse model of human obesity. Life Sci 2015;133:15-20. Go to original source... Go to PubMed...
  11. Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001;58(5-6):737-47. Go to original source... Go to PubMed...
  12. Parkinson A, Ogilvie BW. Biotransformation of xenobiotics: McGraw-Hill New York 2001.
  13. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138(1):103-41. Go to original source... Go to PubMed...
  14. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 2007;76(3):391-6. Go to PubMed...
  15. Guengerich FP. Cytochromes P450, drugs, and diseases. Mol Interv 2003;3(4):194-204. Go to original source... Go to PubMed...
  16. Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006;2(6):875-94. Go to original source... Go to PubMed...
  17. Ogu CC, Maxa JL. Drug interactions due to cytochrome P450. Proc (Bayl Univ Med Cent) 2000;13(4):421-3. Go to PubMed...
  18. Chiney MS, Schwarzenberg SJ, Johnson LA. Altered xanthine oxidase and N-acetyltransferase activity in obese children. Br J Clin Pharmacol 2011;72(1):109-15. Go to original source... Go to PubMed...
  19. Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet 2012;51(5):277-304. Go to original source... Go to PubMed...
  20. Watson AM, Poloyac SM, Howard G, Blouin RA. Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse. Drug Metab Dispos 1999;27(6):695-700. Go to PubMed...
  21. Yoshinari K, Takagi S, Sugatani J, Miwa M. Changes in the expression of cytochromes P450 and nuclear receptors in the liver of genetically diabetic db/db mice. Biol Pharm Bull 2006;29(8):1634-8. Go to original source... Go to PubMed...
  22. Hakkak R, Macleod S, Korourian S. Effects of obesity and 7, 12-dimethylbenz(a)anthracene (DMBA) treatment on liver cytochrome P4501A1 and 1B1 expression in ovariectomized obese Zucker rats. J Mol Genet Med 2013;S1:003.
  23. Suh YH, Kim Y, Bang JH, Choi KS, Lee JW, Kim WH, Oh TJ, An S, Jung MH. Analysis of gene expression profiles in insulin-sensitive tissues from pre-diabetic and diabetic Zucker diabetic fatty rats. J Mol Endocrinol 2005;34(2):299-315. Go to original source... Go to PubMed...
  24. Zhang WV, Ramzan I, Murray M. Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis. J Pharmacol Exp Ther 2007;322(2):770-7. Go to original source... Go to PubMed...
  25. DuBois BN, O'Tierney-Ginn P, Pearson J, Friedman JE, Thornburg K, Cherala G. Maternal obesity alters feto-placental cytochrome P4501A1 activity. Placenta 2012;33(12):1045-51. Go to original source... Go to PubMed...
  26. Raunio H, Juvonen R, Pasanen M, Pelkonen O, Paakko P, Soini Y. Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma. Hepatology 1998;27(2):427-32. Go to original source... Go to PubMed...
  27. Raunio H, Rahnasto-Rilla M. CYP2A6: genetics, structure, regulation, and function. Drug Metabol Drug Interact 2012;27(2):73-88. Go to original source... Go to PubMed...
  28. Xu C, Goodz S, Sellers EM, Tyndale RF. CYP2A6 genetic variation and potential consequences. Adv Drug Deliv Rev 2002;54(10):1245-56. Go to original source... Go to PubMed...
  29. Le Gal A, Dreano Y, Lucas D, Berthou F. Diversity of selective environmental substrates for human cytochrome P450 2A6: alkoxyethers, nicotine, coumarin, N-nitrosodiethylamine, and N-nitrosobenzylmethylamine. Toxicol Lett 2003;144(1):77-91. Go to original source... Go to PubMed...
  30. Abu-Bakar A, Arthur DM, Wikman AS, Rahnasto M, Juvonen RO, Vepsalainen J, Raunio H, Ng JC, Lang MA. Metabolism of bilirubin by human cytochrome P450 2A6. Toxicol Appl Pharmacol 2012;261(1):50-8. Go to original source... Go to PubMed...
  31. Donato MT, Jimenez N, Serralta A, Mir J, Castell JV, Gomez-Lechon MJ. Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. Toxicol In Vitro 2007;21(2):271-6. Go to original source... Go to PubMed...
  32. Cheng Q, Aleksunes LM, Manautou JE, Cherrington NJ, Scheffer GL, Yamasaki H, Slitt AL. Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. Mol Pharm 2008;5(1):77-91. Go to original source... Go to PubMed...
  33. Turpeinen M, Zanger UM. Cytochrome P450 2B6: function, genetics, and clinical relevance. Drug Metabol Drug Interact 2012;27(4):185-97. Go to original source... Go to PubMed...
  34. Yamanaka H, Nakajima M, Fukami T, Sakai H, Nakamura A, Katoh M, Takamiya M, Aoki Y, Yokoi T. CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab Dispos 2005;33(12):1811-8. Go to original source... Go to PubMed...
  35. Xiong H, Yoshinari K, Brouwer KL, Negishi M. Role of constitutive androstane receptor in the in vivo induction of Mrp3 and CYP2B1/2 by phenobarbital. Drug Metab Dispos 2002;30(8):918-23. Go to original source... Go to PubMed...
  36. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52(4):349-55. Go to original source... Go to PubMed...
  37. Sweeney BP, Bromilow J. Liver enzyme induction and inhibition: implications for anaesthesia. Anaesthesia 2006;61(2):159-77. Go to original source... Go to PubMed...
  38. Johannessen SI, Landmark CJ. Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol 2010;8(3):254-67. Go to original source... Go to PubMed...
  39. Steimer W, Zöpf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, Messner B, Kissling W, Leucht S. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 2005;51(2):376-85. Go to original source... Go to PubMed...
  40. Bertilsson L, Dahl ML, Dalén P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002;53(2):111-22. Go to original source... Go to PubMed...
  41. Cravotto G, Boffa L, Genzini L, Garella D. Phytotherapeutics: an evaluation of the potential of 1000 plants. J Clin Pharm Ther 2010;35(1):11-48. Go to original source... Go to PubMed...
  42. Cheymol G, Woestenborghs R, Snoeck E, Ianucci R, Le Moing JP, Naditch L, Levron JC, Poirier JM. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol 1997;51(6):493-8. Go to original source... Go to PubMed...
  43. Badyal DK, Dadhich AP. Cytochrome P450 and drug interactions. Indian J Pharmacol 2001;33:248-59.
  44. Dostalek M, Court MH, Yan B, Akhlaghi F. Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. Br J Pharmacol 2011;163(5):937-47. Go to original source... Go to PubMed...
  45. Khemawoot P, Yokogawa K, Shimada T, Miyamoto K. Obesity-induced increase of CYP2E1 activity and its effect on disposition kinetics of chlorzoxazone in Zucker rats. Biochem Pharmacol 2007;73(1):155-62. Go to original source... Go to PubMed...
  46. Enriquez A, Leclercq I, Farrell GC, Robertson G. Altered expression of hepatic CYP2E1 and CYP4A in obese, diabetic ob/ob mice, and fa/fa Zucker rats. Biochem Biophys Res Commun 1999;255(2):300-6. Go to original source... Go to PubMed...
  47. Matalova P, Urbanek K, Anzenbacher P. Specific features of pharmacokinetics in children. Drug Metab Rev 2016;48(1):70-9. Go to original source... Go to PubMed...
  48. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002;360(9340):1155-62. Go to original source... Go to PubMed...
  49. Wang T, Shankar K, Ronis MJ, Mehendale HM. Mechanisms and outcomes of drug- and toxicant-induced liver toxicity in diabetes. Crit Rev Toxicol 2007;37(5):413-59. Go to original source... Go to PubMed...
  50. Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 1999;37(1):8-19. Go to PubMed...
  51. Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem YF. Alterations of CYP3A4 and P-glycoprotein activity in vivo with time in renal graft recipients. Kidney Int 2004;66(1):433-40. Go to original source... Go to PubMed...
  52. Li XS, Nielsen J, Cirincione B, Li H, Addy C, Wagner J, Hartford A, Erondu N, Gantz I, Morgan J, Stone J. Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist. AAPS J 2010;12(4):537-47. Go to original source... Go to PubMed...
  53. Yoshinari K, Takagi S, Yoshimasa T, Sugatani J, Miwa M. Hepatic CYP3A expression is attenuated in obese mice fed a high-fat diet. Pharm Res 2006;23(6):1188-200. Go to original source... Go to PubMed...
  54. Ghose R, Omoluabi O, Gandhi A, Shah P, Strohacker K, Carpenter KC, McFarlin B, Guo T. Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sci 2011;89(1-2):57-64. Go to original source... Go to PubMed...
  55. Gandhi A, Moorthy B, Ghose R. Drug disposition in pathophysiological conditions. Curr Drug Metab 2012;13(9):1327-44. Go to original source... Go to PubMed...
  56. Galyfos G, Geropapas GI, Kerasidis S, Sianou A, Sigala F, Filis K. The effect of body mass index on major outcomes after vascular surgery. J Vasc Surg 2016;pii:S0741-5214(16)31274-5.
  57. O'Neill AM, Burrington CM, Gillaspie EA, Lynch DT, Horsman MJ, Greene MW. High-fat Western diet-induced obesity contributes to increased tumor growth in mouse models of human colon cancer. Nutr Res 2016;pii:S0271-5317(16)30565-6.
  58. Raunio H, Rautio A, Gullsten H, Pelkonen O. Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol 2001;52(4):357-63. Go to original source... Go to PubMed...
  59. Bousova I, Matouskova P, Bartikova H, Szotakova B, Hanusova V, Tomankova V, Anzenbacherova E, Liskova B, Anzenbacher P, Skalova L. Influence of diet supplementation with green tea extract on drug-metabolizing enzymes in a mouse model of monosodium glutamate-induced obesity. Eur J Nutr 2016;55(1):361-71. Go to original source... Go to PubMed...
  60. Zhang W, Kilicarslan T, Tyndale RF, Sellers EM. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos 2001;29(6):897-902. Go to PubMed...
  61. Pelkonen O, Rautio A, Raunio H, Pasanen M. CYP2A6: a human coumarin 7-hydroxylase. Toxicology 2000;144(1-3):139-47. Go to original source... Go to PubMed...
  62. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 1998;28(12):1203-53. Go to original source... Go to PubMed...
  63. Lewis DFV, Dickins M. Substrate SARs in human P450s. Drug Discov Today 2002;7(17):918-25. Go to original source... Go to PubMed...
  64. Pernecky SJ, Porter TD, Coon MJ. Expression of rabbit cytochrome P-450IIE2 in yeast and stabilization of the enzyme by 4-methylpyrazole. Biochem Biophys Res Commun 1990;172(3):1331-7. Go to original source... Go to PubMed...
  65. Kenworthy K, Bloomer J, Clarke S, Houston J. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 1999;48(5):716-27. Go to original source... Go to PubMed...
  66. Patoine D, Petit M, Pilote S, Picard F, Drolet B, Simard C. Modulation of CYP3a expression and activity in mice models of type 1 and type 2 diabetes. Pharmacol Res Perspect 2014;2(6):e00082. Go to original source... Go to PubMed...
  67. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001;69(3):158-68. Go to original source... Go to PubMed...
  68. Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, Orza D, Marinina J, Gerber N. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 1998;26(6):552-61. Go to PubMed...
  69. Warrington JS, Shader RI, von Moltke LL, Greenblatt DJ. In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos 2000;28(4):392-7. Go to PubMed...
  70. Delaforge M, Jaouen M, Mansuy D. The cytochrome P-450 metabolite complex derived from troleandomycin: properties in vitro and stability in vivo. Chem Biol Interact 1984;51(3):371-6. Go to original source... Go to PubMed...
  71. Kanasaki K, Koya D. Biology of obesity: lessons from animal models of obesity. J Biomed Biotechnol 2011;2011. Go to original source...
  72. Kim S, Sohn I, Ahn JI, Lee KH, Lee YS, Lee YS. Hepatic gene expression profiles in a long-term high-fat diet-induced obesity mouse model. Gene 2004;340(1):99-109. Go to original source... Go to PubMed...
  73. Lutz TA, Woods SC. Overview of animal models of obesity. Curr Protoc Pharmacol 2012;Chapter 5:Unit5.61.
  74. Bultman SJ, Michaud EJ, Woychik RP. Molecular characterization of the mouse agouti locus. Cell 1992;71(7):1195-204. Go to original source... Go to PubMed...
  75. Chen D, Garg A. Monogenic disorders of obesity and body fat distribution. J Lipid Res 1999;40(10):1735-46. Go to PubMed...
  76. O'Rahilly S. Human genetics illuminates the paths to metabolic disease. Nature 2009;462(7271):307-14. Go to original source... Go to PubMed...
  77. Speakman J, Hambly C, Mitchell S, Krol E. Animal models of obesity. Obes Rev 2007;8(s1):55-61. Go to original source... Go to PubMed...
  78. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008;26(2):77-82. Go to original source... Go to PubMed...
  79. Collins S, Martin TL, Surwit RS, Robidoux J. Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: physiological and molecular characteristics. Physiol Behav 2004;81(2):243-8. Go to original source... Go to PubMed...
  80. Nilsson C, Raun K, Yan FF, Larsen MO, Tang-Christensen M. Laboratory animals as surrogate models of human obesity. Acta Pharmacol Sin 2012;33(2):173-81. Go to original source... Go to PubMed...
  81. Hariri N, Thibault L. High-fat diet-induced obesity in animal models. Nutr Res Rev 2010;23(2):270-99. Go to original source... Go to PubMed...
  82. Lin S, Thomas TC, Storlien LH, Huang XF. Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice. Int J Obes 2000;24(5):639-46. Go to original source... Go to PubMed...
  83. Islam MS, Wilson RD. Experimentally induced rodent models of type 2 diabetes. Methods Mol Biol 2012;933:161-74. Go to PubMed...
  84. LeRoith D, Taylor SI, Olefsky JM. Diabetes mellitus: a fundamental and clinical text: Lippincott Williams & Wilkins 2004.
  85. Lobato NS, Filgueira FP, Akamine EH, Davel AP, Rossoni LV, Tostes RC, Carvalho MH, Fortes ZB. Obesity induced by neonatal treatment with monosodium glutamate impairs microvascular reactivity in adult rats: role of NO and prostanoids. Nutr Metab Cardiovasc Dis 2011;21(10):808-16. Go to original source... Go to PubMed...